Abstract
We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. PCR-RFLP and sequencing analyses technique were used for evaluating fourteen previously identified polymorphisms in 94 patients. GSTP1A > G and MTHFR 1298A > C genotypes remained as significant predictors in a multivariate logistic regression analysis. GSTP1 polymorphism was linked to haematological GIII-IV toxicity (P = 0.044, HR= 6.4, 95% CI = 1.05 to 39. Increased and significant HR was obtained for MTHFR-1298 AC+CC group when non-haematological toxicities GIII-IV toxicities were evaluated (HR = 24; 95% CI = 2.3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline- based treatment of breast cancer.
Keywords: Anthracycline, breast cancer, drug-metabolizing enzymes, GSTP1, MTHFR, polymorphisms
Current Drug Metabolism
Title: GSTP1 and MTHFR Polymorphisms Are Related with Toxicity in Breast Cancer Adjuvant Anthracycline-Based Treatment
Volume: 8 Issue: 5
Author(s): R. Zarate, S. Gonzalez-Santiago, E. Bandres, R. Morales, J. Salgado, A. Gomez, E. Aranda and J. Garcia-Foncillas
Affiliation:
Keywords: Anthracycline, breast cancer, drug-metabolizing enzymes, GSTP1, MTHFR, polymorphisms
Abstract: We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. PCR-RFLP and sequencing analyses technique were used for evaluating fourteen previously identified polymorphisms in 94 patients. GSTP1A > G and MTHFR 1298A > C genotypes remained as significant predictors in a multivariate logistic regression analysis. GSTP1 polymorphism was linked to haematological GIII-IV toxicity (P = 0.044, HR= 6.4, 95% CI = 1.05 to 39. Increased and significant HR was obtained for MTHFR-1298 AC+CC group when non-haematological toxicities GIII-IV toxicities were evaluated (HR = 24; 95% CI = 2.3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline- based treatment of breast cancer.
Export Options
About this article
Cite this article as:
R. Zarate , S. Gonzalez-Santiago , E. Bandres , R. Morales , J. Salgado , A. Gomez , E. Aranda and J. Garcia-Foncillas , GSTP1 and MTHFR Polymorphisms Are Related with Toxicity in Breast Cancer Adjuvant Anthracycline-Based Treatment, Current Drug Metabolism 2007; 8 (5) . https://dx.doi.org/10.2174/138920007780866780
DOI https://dx.doi.org/10.2174/138920007780866780 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
Current Drug Metabolism Genetic Dissection of Complex Traits In Silico: Approaches, Problems and Solutions
Current Bioinformatics Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Management of Vulvar Cancer
Reviews on Recent Clinical Trials lncRNA HOTAIR, HOXC11 and HOXC12 Gene Expressions are Upregulated in CaCo2 Cells Treated with P31-43 Toxic Peptide
Current Signal Transduction Therapy Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
Current Pharmaceutical Design Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2
Current Cancer Drug Targets Cancer Stem Cells and Therapeutic Perspectives
Current Medicinal Chemistry PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Molecular Mechanisms of Anticancer Effects of Phytoestrogens in Breast Cancer
Current Protein & Peptide Science <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Protein & Peptide Letters Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Periplogenin Activates ROS-ER Stress Pathway to Trigger Apoptosis via BIP-eIF2α- CHOP and IRE1α-ASK1-JNK Signaling Routes
Anti-Cancer Agents in Medicinal Chemistry